688180 君實生物
按盤價 
36.360 +0.360 (+1.000%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 1,805,880 | 42.06% | 1,948,317 | 1,502,550 | 1,453,493 | 4,024,841 | |
| 減：營業總成本 | 2,473,163 | 9.38% | 3,215,859 | 3,811,860 | 4,102,931 | 4,728,260 | |
| 其中:營業成本 | 349,485 | 7.42% | 410,682 | 540,976 | 504,308 | 1,244,540 | |
| 財務費用 | 46,333 | 514.57% | (144) | (67,086) | (80,955) | 31,366 | |
| 資產減值損失 | (69,246) | 1,801.45% | (88,179) | (126,314) | (21,974) | (13,647) | |
| 公允價值變動收益 | 58,016 | -293.04% | (47,679) | (149,177) | (9,277) | 112,933 | |
| 投資收益 | (38,851) | 126.57% | (23,554) | 73,990 | (41,932) | (47,187) | |
| 其中：對聯營企業和合營企業的投資收益 | (46,163) | 88.85% | (35,026) | (60,485) | (71,031) | (48,463) | |
| 營業利潤 | (671,058) | -30.76% | (1,338,825) | (2,457,442) | (2,665,914) | (558,275) | |
| 利潤總額 | (692,393) | -29.68% | (1,357,557) | (2,491,695) | (2,677,184) | (595,000) | |
| 減：所得稅費用 | (18,083) | -543.04% | 22,552 | 43,995 | (93,107) | 135,533 | |
| 淨利潤 | (674,310) | -31.80% | (1,380,109) | (2,535,689) | (2,584,077) | (730,534) | |
| 減：非控股權益 | (78,610) | 26.88% | (99,182) | (252,257) | (196,028) | (9,624) | |
| 股東淨利潤 | (595,700) | -35.72% | (1,280,926) | (2,283,432) | (2,388,050) | (720,910) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.600 | -36.17% | -1.300 | -2.320 | -2.600 | -0.810 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 6.055 | -3.31% | 5.946 | 7.260 | 9.650 | 8.720 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 08/12/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
